---
title: "TVRD.US (TVRD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TVRD.US/news.md"
symbol: "TVRD.US"
name: "TVRD.US"
parent: "https://longbridge.com/en/quote/TVRD.US.md"
datetime: "2026-03-05T12:33:46.983Z"
locales:
  - [en](https://longbridge.com/en/quote/TVRD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TVRD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TVRD.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/TVRD.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/TVRD.US/news.md)


# TVRD.US (TVRD.US) — Related News

### [Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases](https://longbridge.com/en/news/272760862.md)
*2026-01-16T00:04:54.000Z*
> Tvardi Therapeutics Inc. has unveiled a corporate presentation detailing its progress in developing STAT3 inhibitors for

### [Tvardi Therapeutics to present new data from Phase 2 REVERT IPF Clinical Trial at J.P. Morgan Healthcare Conference.](https://longbridge.com/en/news/271985751.md)
*2026-01-08T21:07:58.000Z*
> Tvardi Therapeutics will present new findings from its Phase 2 REVERT IPF clinical trial of TTI-101 at the J.P. Morgan H

### [Tvardi Therapeutics Reports Phase 2 Data Showing TTI-101 Reduces Fibrosis in IPF Patients](https://longbridge.com/en/news/271936788.md)
*2026-01-08T13:02:53.000Z*
> Tvardi Therapeutics Inc. has reported updates from its Phase 2 REVERT IPF clinical trial for TTI-101, an oral STAT3 inhi

### [12 Health Care Stocks Moving In Wednesday's Pre-Market Session](https://longbridge.com/en/news/271216621.md)
*2025-12-31T12:06:05.000Z*
> In Wednesday's pre-market session, several health care stocks saw significant movements. Specimen (ISPC) rose 20.4% to $

### [Tvardi Therapeutics Approves New Severance and Retention Compensation Plan for Executives](https://longbridge.com/en/news/270216350.md)
*2025-12-18T22:21:55.000Z*
> Tvardi Therapeutics Inc. has approved a one-time retention compensation package for its named executive officers, includ

### [Faruqi & Faruqi, LLP investigates claims for Tvardi Therapeutics investors. Contact James Wilson if significant losses occurred.](https://longbridge.com/en/news/269403931.md)
*2025-12-11T15:16:09.000Z*
> Securities Litigation Partner James (Josh) Wilson of Faruqi & Faruqi, LLP is urging investors who have experienced subst

### [Investors of Tvardi Therapeutics facing significant losses urged to contact Faruqi & Faruqi, LLP before deadline. Contact James Wilson for assistance.](https://longbridge.com/en/news/268641553.md)
*2025-12-04T15:30:28.000Z*
> Securities Litigation Partner James (Josh) Wilson from Faruqi & Faruqi, LLP is urging investors who experienced substant

### [Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario](https://longbridge.com/en/news/266968596.md)
*2025-11-21T17:45:23.000Z*
> JonesTrading analyst Debanjana Chatterjee reaffirmed a Buy rating for Tvardi Therapeutics, citing upcoming catalysts lik